Aldeyra announces FDA acceptance of resubmitted reproxalap application

Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular reproxalap for the treatment of dry eye disease and an expansion of its option agreement with AbbVie (NYSE:ABBV).

The biotech company said the FDA has assigned